ALVO · Alvotech

Alvotech completed a significant capital raise through a registered public offering and an exempt concurrent private placement, both priced at $3.75 per ordinary share. The public offering of 26,066,667 shares (including full exercise of the underwriters' option for an additional 3.4 million shares) closed on June 17, 2026, generating gross proceeds of approximately $98 million. The concurrent private placement of 17,826,666 shares, exempt from SEC registration under applicable European regulations, is expected to close on June 25, 2026, adding roughly $67 million. Total gross proceeds of ~$165 million will be directed toward advancing Alvotech's biosimilar pipeline (including nine disclosed candidates targeting autoimmune, ophthalmic, osteoporosis, respiratory, and cancer indications), as well as working capital, IP enforcement, commercial and capital expenditures, potential acquisitions, and debt servicing. The offerings were managed by BofA Securities, Jefferies, and Evercore ISI. Following the private placement, Alvotech's issued share capital will increase to 390,431,480 ordinary shares. This capital infusion strengthens the company's balance sheet and supports its strategy to expand biosimilar commercialization and development globally.